Androstanolone

Last updated

Androstanolone
Androstanolone.svg
Dihydrotestosterone molecule ball.png
Clinical data
Trade names Andractim, others
Other namesStanolone; Dihydrotestosterone; DHT; 5α-Dihydrotestosterone; 5α-DHT
Pregnancy
category
  • X
Routes of
administration 		Transdermal (gel), in the cheek, under the tongue, intramuscular injection (as esters)
Drug class Androgen; Anabolic steroid
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Oral: Very low [2]
Transdermal: 10% [2] [3]
IM injection: 100% [3]
Metabolism Liver
Elimination half-life Transdermal: 2.8 hours [4]
Excretion Urine
Identifiers
  • (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
Formula C19H30O2
Molar mass 290.447 g·mol−1
3D model (JSmol)
  • O=C4C[C@@H]3CC[C@@H]2[C@H](CC[C@]1(C)[C@@H](O)CC[C@H]12)[C@@]3(C)CC4
  • InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1 Yes check.svgY
  • Key:NVKAWKQGWWIWPM-ABEVXSGRSA-N Yes check.svgY
   (verify)

Androstanolone, or stanolone, also known as dihydrotestosterone (DHT) and sold under the brand name Andractim among others, is an androgen and anabolic steroid (AAS) medication and hormone which is used mainly in the treatment of low testosterone levels in men. [2] It is also used to treat breast development and small penis in males. [2] Compared to testosterone, androstanolone (DHT) is less likely to aromatize into estrogen, and therefore it shows less pronounced estrogenic side effects, such as gynecomastia and water retention. On the other hand, androstanolone (DHT) show more significant androgenic side effects, such as acne, hair loss and prostate enlargement.

Contents

It has strong androgenic effects and muscle-building effects, as well as relatively weak estrogenic effects. [2]

It is typically given as a gel for application to the skin, but can also be used as an ester by injection into muscle. [2] [5]

Side effects of androstanolone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. [2] The medication is a naturally occurring androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and DHT. [2] [6]

Androstanolone was discovered in 1935 and was introduced for medical use in 1953. [2] [7] [8] [9] It is used mostly in France and Belgium. [2] [10] [11] The drug has been used by weightlifters to increase performance due to its powerful androgenic properties. [12] [13] The medication is a controlled substance in many countries and so non-medical use is generally illicit. [2]

Medical uses

Androstanolone is available in pharmaceutical formulations for medical use as an androgen. [5] It is used mainly as a form of androgen replacement therapy in the treatment of male hypogonadism and is specifically approved for this indication in certain countries. [14] [15] [16] [17] [18] [19] [11] However, it is no longer recommended for this purpose due to biological differences from testosterone such as lack of estrogenic effects and partial androgenic effects. [20] Topical androstanolone is useful in the treatment of gynecomastia. [21] Similarly, androstanolone enanthate via intramuscular injection has been found to be effective in the treatment persistent pubertal gynecomastia. [22] The medication has also been used as a topical gel to treat small penis in pre- and peripubertal boys with mild or partial androgen insensitivity syndrome. [23] [2] [24]

Androstanolone was found to be effective in the treatment of advanced breast cancer in women in the 1950s, although it was used in very high doses and caused severe virilization. [25] [26] [27] It was used as a microcrystalline aqueous suspension by intramuscular injection. [28] [29] [30] Shortly thereafter, drostanolone propionate (2α-methylandrostanolone propionate) was developed for this use instead of androstanolone due to its superior pharmacokinetics and was introduced for this indication in the United States and Europe in the early 1960s. [31] [32] [33] [34]

Androstanolone was used at a dose of 25 mg sublingually two to three times per day in androgen replacement therapy for men. [35] This is also the anabolic dosage of androstanolone in men. [35]

Androgen replacement therapy formulations and dosages used in men
RouteMedicationMajor brand namesFormDosage
Oral Testosterone a–Tablet400–800 mg/day (in divided doses)
Testosterone undecanoate Andriol, JatenzoCapsule40–80 mg/2–4x day (with meals)
Methyltestosterone bAndroid, Metandren, TestredTablet10–50 mg/day
Fluoxymesterone bHalotestin, Ora-Testryl, UltandrenTablet5–20 mg/day
Metandienone bDianabolTablet5–15 mg/day
Mesterolone bProvironTablet25–150 mg/day
Sublingual Testosterone bTestoralTablet5–10 mg 1–4x/day
Methyltestosterone bMetandren, Oreton MethylTablet10–30 mg/day
Buccal Testosterone StriantTablet30 mg 2x/day
Methyltestosterone bMetandren, Oreton MethylTablet5–25 mg/day
Transdermal Testosterone AndroGel, Testim, TestoGelGel25–125 mg/day
Androderm, AndroPatch, TestoPatchNon-scrotal patch2.5–15 mg/day
TestodermScrotal patch4–6 mg/day
AxironAxillary solution30–120 mg/day
Androstanolone (DHT)AndractimGel100–250 mg/day
Rectal Testosterone Rektandron, TestosteronbSuppository40 mg 2–3x/day
Injection (IM Tooltip intramuscular injection or SC Tooltip subcutaneous injection) Testosterone Andronaq, Sterotate, VirosteroneAqueous suspension10–50 mg 2–3x/week
Testosterone propionate bTestovironOil solution10–50 mg 2–3x/week
Testosterone enanthate DelatestrylOil solution50–250 mg 1x/1–4 weeks
XyostedAuto-injector50–100 mg 1x/week
Testosterone cypionate Depo-TestosteroneOil solution50–250 mg 1x/1–4 weeks
Testosterone isobutyrate Agovirin DepotAqueous suspension50–100 mg 1x/1–2 weeks
Testosterone phenylacetate bPerandren, AndrojectOil solution50–200 mg 1x/3–5 weeks
Mixed testosterone esters Sustanon 100, Sustanon 250Oil solution50–250 mg 1x/2–4 weeks
Testosterone undecanoate Aveed, NebidoOil solution750–1,000 mg 1x/10–14 weeks
Testosterone buciclate a–Aqueous suspension600–1,000 mg 1x/12–20 weeks
Implant Testosterone TestopelPellet150–1,200 mg/3–6 months
Notes: Men produce about 3 to 11 mg testosterone per day (mean 7 mg/day in young men). Footnotes:a = Never marketed. b = No longer used and/or no longer marketed. Sources: See template.
Androgen/anabolic steroid dosages for breast cancer
RouteMedicationFormDosage
Oral Methyltestosterone Tablet30–200 mg/day
Fluoxymesterone Tablet10–40 mg 3x/day
Calusterone Tablet40–80 mg 4x/day
Normethandrone Tablet40 mg/day
Buccal Methyltestosterone Tablet25–100 mg/day
Injection (IM Tooltip intramuscular injection or SC Tooltip subcutaneous injection) Testosterone propionate Oil solution50–100 mg 3x/week
Testosterone enanthate Oil solution200–400 mg 1x/2–4 weeks
Testosterone cypionate Oil solution200–400 mg 1x/2–4 weeks
Mixed testosterone esters Oil solution250 mg 1x/week
Methandriol Aqueous suspension100 mg 3x/week
Androstanolone (DHT)Aqueous suspension300 mg 3x/week
Drostanolone propionate Oil solution100 mg 1–3x/week
Metenolone enanthate Oil solution400 mg 3x/week
Nandrolone decanoate Oil solution50–100 mg 1x/1–3 weeks
Nandrolone phenylpropionate Oil solution50–100 mg/week
Note: Dosages are not necessarily equivalent. Sources: See template.

Available forms

Androstanolone is available as a 2.5% hydroalcoholic gel given transdermally in doses of 5 or 10 g/day (brand name Andractim). [20] The medication was previously available as a 10 mg oral tablet with 300 mg L-lysine (brand name Lysinex) and as a 25 mg sublingual tablet (brand names Anabolex, Anaprotin, Anabolene, Anaboleen, Proteina). [35] [36] The medication has also been marketed in the form of several androstanolone esters, including androstanolone benzoate (brand names Ermalone-Amp, Hermalone, Sarcosan), androstanolone enanthate (brand name Anaboleen Depot), androstanolone propionate (brand name Pesomax), and androstanolone valerate (brand name Apeton), which are provided as oil solutions for intramuscular injection at regular intervals. [37]

Side effects

Adverse effects of androstanolone are similar to those of other AAS and include androgenic side effects like oily skin, acne, seborrhea, increased facial/body hair growth, scalp hair loss, and increased aggressiveness and sex drive. [38] [6] In women, androstanolone can cause partially irreversible virilization, for instance voice deepening, hirsutism, clitoromegaly, breast atrophy, and muscle hypertrophy, as well as menstrual disturbances and reversible infertility. [38] [6] In men, the medication may also cause hypogonadism, testicular atrophy, and reversible infertility at sufficiently high dosages. [38] [6]

Androstanolone can have adverse effects on the cardiovascular system, especially with long-term administration of high dosages. [38] AAS like androstanolone stimulate erythropoiesis (red blood cell production) and increase hematocrit levels and at high dosages can cause polycythemia (overproduction of red blood cells), which can greatly increase the risk of thrombic events such as embolism and stroke. [38] Unlike many other AAS, androstanolone is not aromatized into estrogens and hence has no risk of estrogenic side effects like gynecomastia, fluid retention, or edema. [38] [6] [39] [40] In addition, as it is not a 17α-alkylated AAS and is administered parenterally, androstanolone has no risk of hepatotoxicity. [38] [6]

It has been theorized that androstanolone may have less risk of benign prostatic hyperplasia and prostate cancer than testosterone because it is not aromatized into estrogens. [39] [40] This is relevant because estrogens are thought to possibly be necessary for the manifestation of these diseases. [39] In accordance, androstanolone has been found to not increase prostate gland size in men. [40] Conversely, due to lack of aromatization into estrogens, androstanolone therapy for androgen replacement may result in decreased bone mineral density, incomplete effects in the brain, and undesirable changes in cholesterol levels. [39]

Pharmacology

Pharmacodynamics

Androgenic vs. anabolic activity ratio
of androgens/anabolic steroids
MedicationRatioa
Testosterone ~1:1
Androstanolone (DHT)~1:1
Methyltestosterone ~1:1
Methandriol ~1:1
Fluoxymesterone 1:1–1:15
Metandienone 1:1–1:8
Drostanolone 1:3–1:4
Metenolone 1:2–1:30
Oxymetholone 1:2–1:9
Oxandrolone 1:3–1:13
Stanozolol 1:1–1:30
Nandrolone 1:3–1:16
Ethylestrenol 1:2–1:19
Norethandrolone 1:1–1:20
Notes: In rodents. Footnotes:a = Ratio of androgenic to anabolic activity. Sources: See template.

Androstanolone is a potent agonist of the AR. It has an affinity (Kd) of 0.25 to 0.5 nM for the human AR, which is about 2- to 3-fold higher than that of testosterone (Kd = 0.4 to 1.0 nM) [41] and the dissociation rate of androstanolone from the AR is also about 5-fold slower than that of testosterone. [42] The EC50 of androstanolone for activation of the AR is 0.13 nM, which is about 5-fold stronger than that of testosterone (EC50 = 0.66 nM). [43] In bioassays, androstanolone has been found to be 2.5- to 10-fold more potent than testosterone. [41] Upon intramuscular injection in rats, androstanolone is about 1.5- to 2.5-fold the potency of testosterone. [35]

Unlike testosterone and various other AAS, androstanolone cannot be aromatized, and for this reason, poses no risk of estrogenic side effects like gynecomastia at any dosage. [44] In addition, androstanolone cannot be metabolized by 5α-reductase (as it is already 5α-reduced), and for this reason, is not potentiated in so-called "androgenic" tissues like the skin, hair follicles, and prostate gland, thereby improving its ratio of anabolic to androgenic effects. However, androstanolone is nonetheless described as a very poor anabolic agent. [38] This is attributed to its high affinity as a substrate for 3α-hydroxysteroid dehydrogenase (3α-HSD), which is highly expressed in skeletal muscle and inactivates androstanolone into 3α-androstanediol, a metabolite with very weak AR activity. [38] Unlike androstanolone, testosterone is very resistant to metabolism by 3α-HSD, and so is not similarly inactivated in skeletal muscle. [38] For the preceding reasons, androstanolone has been described as a "partial androgen". [20]

Pharmacokinetics

Absorption

The bioavailability of androstanolone differs considerably depending on its route of administration. [2] [3] Its oral bioavailability is very low, and androstanolone has been considered to be ineffective by the oral route. [2] However, it has been used orally, and is described as a weak AAS by this route. [35] The transdermal bioavailability of androstanolone is approximately 10%. [2] [3] Its bioavailability with intramuscular injection, on the other hand, is complete (100%). [3]

Doses of topical androstanolone gel of 16, 32, and 64 mg have been found to produce total testosterone and DHT levels in the low, mid, and high normal adult male range, respectively. [39]

Distribution

The plasma protein binding of androstanolone is about 98.5 to 99.0%. [45] It is bound 50 to 80% to sex hormone-binding globulin, 20 to 40% to albumin, and less than 0.5% to corticosteroid-binding globulin, with about 1.0 to 1.5% circulating freely or unbound. [45]

Metabolism

The terminal half-life of androstanolone in the circulation (53 minutes) is longer than that of testosterone (34 minutes), and this may account for some of the difference in their potency. [46] A study of transdermal androstanolone and testosterone therapy reported terminal half-lives of 2.83 hours and 1.29 hours, respectively. [4]

Chemistry

Androstanolone, also known as 5α-androstan-17β-ol-3-one or as 5α-dihydrotestosterone (5α-DHT), is a naturally occurring androstane steroid with a ketone group at the C3 position and a hydroxyl group at the C17β position. [37] [47] It is the derivative of testosterone in which the double bond between the C4 and C5 positions has been reduced or hydrogenated. [37] [47]

Esters

Several C17β ester prodrugs of androstanolone, including androstanolone benzoate, androstanolone enanthate, androstanolone propionate, and androstanolone valerate, have been developed and introduced for medical use as AAS. Conversely, dihydrotestosterone acetate, dihydrotestosterone butyrate, and dihydrotestosterone formate have been developed but have not been marketed. [37] [48]

Derivatives

Synthetic derivatives of androstanolone (DHT) that have been developed as AAS include: [2]

History

Androstanolone was first discovered and synthesized in 1935 by Adolf Butenandt and his colleagues. [7] [8] It was first introduced for medical use in 1953, under the brand name Neodrol in the United States, [9] [49] [50] and was subsequently marketed in the United Kingdom and other European countries. [9] Transdermal androstanolone gel has been available in France since 1982. [51]

Society and culture

Generic names

When used as a drug, androstanolone is referred to as androstanolone (INN Tooltip International Nonproprietary Name) or as stanolone (BAN Tooltip British Approved Name) rather than as DHT. [5] [37] [47] [10]

Brand names

Brand names of androstanolone include Anaboleen, Anabolex, Anaprotin (UK), Andractim (formerly AndroGel-DHT) (FR, BE, LU), Androlone, Apeton, Gelovit (ES), Neodrol, Ophtovital (DE), Pesomax (IT), Stanaprol, and Stanolone, among others. [5] [37] [47] [14] [52] [10] [11]

Availability

The availability of pharmaceutical androstanolone is limited; it is not available in the United States or Canada, [53] [54] but it is or has been available in certain European countries, including the United Kingdom, Germany, France, Spain, Italy, Belgium, and Luxembourg. [47] [14] [10] [11] [35]

The available formulations of androstanolone include buccal or sublingual tablets (Anabolex, Stanolone), topical gels (Andractim, Gelovit, Ophtovital), and, as esters in oil, injectables like androstanolone propionate (Pesomax) and androstanolone valerate (Apeton). [5] [14] [52] [35] Androstanolone benzoate (Ermalone-Amp, Hermalone, Sarcosan) and androstanolone enanthate (Anaboleen Depot) are additional androstanolone esters that are available for medical use in some countries. [37] Androstanolone esters act as prodrugs of androstanolone in the body and have a long-lasting depot effect when given via intramuscular injection. [5]

Androstanolone, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act. [55]

Androstanolone is on the World Anti-Doping Agency's list of prohibited substances, [56] and is therefore banned from use in most major sports.

Research

In the early- to mid-2000s, transdermal or topical androstanolone was under development in the United States for the treatment of hypogonadism (as a form of androgen replacement therapy), male osteoporosis, and cachexia (in cancer patients) and in Australia for the treatment of benign prostatic hyperplasia (BPH). [57] [58] [14] It reached phase II clinical trials for hypogonadism and BPH and phase III clinical studies for cachexia but development was ultimately never completed for these indications in these specific countries. [57] [58] [14] Although androstanolone itself has not been approved for cachexia in any country, an orally active synthetic derivative of androstanolone, oxandrolone (2-oxa-17α-methylandrostanolone), is approved and used for this indication in the United States. [59] [60]

Topical androgens like androstanolone have been used and studied in the treatment of cellulite in women. [61] Topical androstanolone on the abdomen has also been found to significantly decrease subcutaneous abdominal fat in women, and hence may be useful for improving body silhouette. [61] However, men and hyperandrogenic women have higher amounts of abdominal fat than healthy women, and androgen therapy has been found to increase abdominal fat in postmenopausal women and transgender men. [62]

Related Research Articles

<span class="mw-page-title-main">Dihydrotestosterone</span> Human hormone

Dihydrotestosterone is an endogenous androgen sex steroid and hormone primarily involved in the growth and repair of the prostate and the penis, as well as the production of sebum and body hair composition.

<span class="mw-page-title-main">Methyltestosterone</span> Chemical compound

Methyltestosterone, sold under the brand names Android, Metandren, and Testred among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, at low doses as a component of menopausal hormone therapy for menopausal symptoms like hot flashes, osteoporosis, and low sexual desire in women, and to treat breast cancer in women. It is taken by mouth or held in the cheek or under the tongue.

<span class="mw-page-title-main">Nandrolone decanoate</span> Anabolic steroid

Nandrolone decanoate, sold under the brand name ROLON among others, is an androgen and anabolic steroid (AAS) medication which is used primarily in the treatment of anemias and wasting syndromes, as well as osteoporosis in menopausal women. It is given by injection into muscle or fat once every one to four weeks.

<span class="mw-page-title-main">Testosterone cypionate</span> Chemical compound

Testosterone cypionate, sold under the brand name Depo-Testosterone among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It is also used in hormone therapy for transgender men. It is given by injection into muscle or subcutaneously, once every one to four weeks, depending on clinical indication.

<span class="mw-page-title-main">Testosterone enanthate</span> Chemical compound

Testosterone enanthate is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It is also used in hormone therapy for transgender men. It is given by injection into muscle or subcutaneously usually once every one to four weeks.

<span class="mw-page-title-main">Testosterone propionate</span> Chemical compound

Testosterone propionate, sold under the brand name Testoviron among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels in men. It has also been used to treat breast cancer in women. It is given by injection into muscle usually once every two to three days.

<span class="mw-page-title-main">Metenolone enanthate</span> Chemical compound

Metenolone enanthate, or methenolone enanthate, sold under the brand names Primobolan Depot and Nibal Injection, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of anemia due to bone marrow failure. It is given by injection into muscle. Although it was widely used in the past, the drug has mostly been discontinued and hence is now mostly only available on the black market. A related drug, metenolone acetate, is taken by mouth.

<span class="mw-page-title-main">Ethylestrenol</span> Chemical compound

Ethylestrenol, also known as ethyloestrenol or ethylnandrol and sold under the brand names Maxibolin and Orabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used in the past for a variety of indications such as to promote weight gain and to treat anemia and osteoporosis but has been discontinued for use in humans. It is still available for veterinary use in Australia and New Zealand however. It is taken by mouth.

<span class="mw-page-title-main">Mesterolone</span> Chemical compound

Mesterolone, sold under the brand name Proviron among others, is an androgen and anabolic steroid (AAS) medication which is used mainly in the treatment of low testosterone levels. It has also been used to treat male infertility, although this use is controversial. It is taken by mouth.

<span class="mw-page-title-main">Fluoxymesterone</span> Chemical compound

Fluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, breast cancer in women, and anemia. It is taken by mouth.

<span class="mw-page-title-main">Trestolone</span> Chemical compound

Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is an experimental androgen/anabolic steroid (AAS) and progestogen medication which has been under development for potential use as a form of hormonal birth control for men and in androgen replacement therapy for low testosterone levels in men but has never been marketed for medical use. It is given as an implant that is placed into fat. As trestolone acetate, an androgen ester and prodrug of trestolone, the medication can also be given by injection into muscle.

<span class="mw-page-title-main">Drostanolone propionate</span> Chemical compound

Drostanolone propionate, or dromostanolone propionate, sold under the brand names Drolban, Masteril, and Masteron among others, is an androgen and anabolic steroid (AAS) medication which was used to treat breast cancer in women but is now no longer marketed. It is given by injection into muscle.

<span class="mw-page-title-main">Mestanolone</span> Chemical compound

Mestanolone, also known as methylandrostanolone and sold under the brand names Androstalone and Ermalone among others, is an androgen and anabolic steroid (AAS) medication which is mostly no longer used. It is still available for use in Japan however. It is taken by mouth.

<span class="mw-page-title-main">Anabolic steroid</span> Steroidal androgen that is structurally related and has similar effects to testosterone

Anabolic steroids, also known as anabolic-androgenic steroids (AAS), are a class of drugs that are structurally related to testosterone, the main male sex hormone, and produce effects by binding to the androgen receptor. Anabolic steroids have a number of medical uses, but are also used by athletes to increase muscle size, strength, and performance.

<span class="mw-page-title-main">Androgen ester</span> Class of chemical compounds

An androgen or anabolic steroid ester is an ester of an androgen/anabolic steroid (AAS) such as the natural testosterone or dihydrotestosterone (DHT) or the synthetic nandrolone (19-nortestosterone). Esterification renders AAS into metabolism-resistant prohormones of themselves, improving oral bioavailability, increasing lipophilicity, and extending the elimination half-life. In addition, with intramuscular injection, AAS esters are absorbed more slowly into the body, further improving the elimination half-life. Aside from differences in pharmacokinetics, these esters essentially have the same effects as the parent drugs. They are used in androgen replacement therapy (ART), among other indications. Examples of androgen esters include testosterone esters such as testosterone cypionate, testosterone enanthate, testosterone propionate, and testosterone undecanoate and nandrolone esters such as nandrolone decanoate and nandrolone phenylpropionate.

<span class="mw-page-title-main">Nandrolone phenylpropionate</span> Anabolic steroid

Nandrolone phenylpropionate (NPP), or nandrolone phenpropionate, sold under the brand name Durabolin among others, is an androgen and anabolic steroid (AAS) medication which has been used primarily in the treatment of breast cancer and osteoporosis in women. It is given by injection into muscle once every week. Although it was widely used in the past, the drug has mostly been discontinued and hence is now mostly no longer available.

<span class="mw-page-title-main">Steroidal antiandrogen</span> Class of compounds

A steroidal antiandrogen (SAA) is an antiandrogen with a steroidal chemical structure. They are typically antagonists of the androgen receptor (AR) and act both by blocking the effects of androgens like testosterone and dihydrotestosterone (DHT) and by suppressing gonadal androgen production. SAAs lower concentrations of testosterone through simulation of the negative feedback inhibition of the hypothalamus. SAAs are used in the treatment of androgen-dependent conditions in men and women, and are also used in veterinary medicine for the same purpose. They are the converse of nonsteroidal antiandrogens (NSAAs), which are antiandrogens that are not steroids and are structurally unrelated to testosterone.

<span class="mw-page-title-main">Testosterone (medication)</span> Medication and naturally occurring steroid hormone

Testosterone (T) is a medication and naturally occurring steroid hormone. It is used to treat male hypogonadism, gender dysphoria, and certain types of breast cancer. It may also be used to increase athletic ability in the form of doping. It is unclear if the use of testosterone for low levels due to aging is beneficial or harmful. Testosterone can be used as a gel or patch that is applied to the skin, injection into a muscle, tablet that is placed in the cheek, or tablet that is taken by mouth.

References

  1. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Llewellyn W (2011). Anabolics. Molecular Nutrition Llc. pp. 8, 23–25, 353–359. ISBN   978-0-9828280-1-4.
  3. 1 2 3 4 5 Coutts SB, Kicman AT, Hurst DT, Cowan DA (November 1997). "Intramuscular administration of 5 alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile". Clinical Chemistry. 43 (11): 2091–2098. doi: 10.1093/clinchem/43.11.2091 . PMID   9365393.
  4. 1 2 von Deutsch DA, Abukhalaf IK, Lapu-Bula R (15 October 2003). "Anabolic Doping Agents". In Mozayani A, Raymon L (eds.). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 510–. doi:10.1007/978-1-61779-222-9_15. ISBN   978-1-59259-654-6.
  5. 1 2 3 4 5 6 Hyde TE, Gengenbach MS (2007). Conservative Management of Sports Injuries. Jones & Bartlett Learning. pp. 1100–. ISBN   978-0-7637-3252-3.
  6. 1 2 3 4 5 6 Kicman AT (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology. 154 (3): 502–521. doi:10.1038/bjp.2008.165. PMC   2439524 . PMID   18500378.
  7. 1 2 Schnitzer R (1 January 1967). Experimental Chemotherapy. Elsevier Science. pp. 156–. ISBN   978-0-323-14611-1.
  8. 1 2 Krüskemper HL (22 October 2013). Anabolic Steroids. Elsevier. pp. 12–. ISBN   978-1-4832-6504-9.
  9. 1 2 3 Sittig M (2007). Pharmaceutical Manufacturing Encyclopedia. William Andrew Publishing. ISBN   978-0-8155-1526-5.
  10. 1 2 3 4 "Androstanolone".
  11. 1 2 3 4 Gooren LJ, Bunck MC (2004). "Androgen replacement therapy: present and future". Drugs. 64 (17): 1861–1891. doi:10.2165/00003495-200464170-00002. PMID   15329035. S2CID   46959273.
  12. ↑ "Public Disclosure". 30 May 2018.
  13. ↑ "Steroid Use by Chinese Hints at Systematic Doping". Chicago Tribune . 10 December 1994.
  14. 1 2 3 4 5 6 "Androstanolone". AdisInsight. Springer Nature Switzerland AG.
  15. ↑ Wang C, Swerdloff RS (October 1997). "Androgen replacement therapy". Annals of Medicine. 29 (5): 365–370. doi: 10.3109/07853899708999363 . PMID   9453281.
  16. ↑ Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA (June 2017). "Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels". Endocrine Reviews. 38 (3): 220–254. doi:10.1210/er.2016-1067. PMC   6459338 . PMID   28472278.
  17. ↑ Swerdloff RS, Wang C (October 1998). "Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent". Baillière's Clinical Endocrinology and Metabolism. 12 (3): 501–506. doi:10.1016/S0950-351X(98)80267-X. PMID   10332569.
  18. ↑ Wang C, Swerdloff RS (April 2002). "Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause?". The Journal of Clinical Endocrinology and Metabolism. 87 (4): 1462–1466. doi: 10.1210/jcem.87.4.8488 . PMID   11932265.
  19. ↑ Byrne M, Nieschlag E (May 2003). "Testosterone replacement therapy in male hypogonadism". Journal of Endocrinological Investigation. 26 (5): 481–489. doi:10.1007/BF03345206. PMID   12906378. S2CID   19557568.
  20. 1 2 3 Rastrelli G, Guaraldi F, Reismann Y, Sforza A, Isidori AM, Maggi M, Corona G (July 2019). "Testosterone Replacement Therapy". Sexual Medicine. Vol. 7. Springer. pp. 464–475. doi: 10.1007/978-981-13-1226-7_8 . ISBN   978-981-13-1225-0. PMID   30803919.{{cite book}}: |journal= ignored (help)
  21. ↑ Agrawal S, Ganie MA, Nisar S (2017). "Gynaecomastia". Basics of Human Andrology. Singapore: Springer. pp. 451–458. doi:10.1007/978-981-10-3695-8_26. ISBN   978-981-10-3694-1.
  22. ↑ Eberle AJ, Sparrow JT, Keenan BS (July 1986). "Treatment of persistent pubertal gynecomastia with dihydrotestosterone heptanoate". The Journal of Pediatrics. 109 (1): 144–149. doi:10.1016/S0022-3476(86)80596-0. PMID   3088241.
  23. ↑ Hohl A (30 March 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 91–. ISBN   978-3-319-46086-4.
  24. ↑ Becker D, Wain LM, Chong YH, Gosai SJ, Henderson NK, Milburn J, et al. (February 2016). "Topical dihydrotestosterone to treat micropenis secondary to partial androgen insensitivity syndrome (PAIS) before, during, and after puberty - a case series". Journal of Pediatric Endocrinology & Metabolism. 29 (2): 173–177. doi:10.1515/jpem-2015-0175. PMID   26352087. S2CID   30671775.
  25. ↑ Gelhorn A, Holland J, Herrmann JB, Moss J, Smelin A (April 1954). "An evaluation of stanolone in treatment of advanced mammary cancer". Journal of the American Medical Association. 154 (15): 1274–1277. doi:10.1001/jama.1954.02940490038010. PMID   13151839.
  26. ↑ Kennedy BJ (1955). "The effect of stanolone in the treatment of advanced breast cancer". Cancer. 8 (3): 488–497. doi: 10.1002/1097-0142(1955)8:3<488::AID-CNCR2820080309>3.0.CO;2-Y . PMID   14379136. S2CID   5330089.
  27. ↑ Segaloff A, Horwitt BN, Carabasi RA, Murison PJ, Schlosser JV (1955). "Hormonal therapy in cancer of the breast. VIII. The effect of dihydrotestosterone (androstanolone) on clinical course and hormonal excretion". Cancer. 8 (1): 82–86. doi: 10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R . PMID   13231036.
  28. ↑ Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DJ (eds.). Antineoplastic and Immunosuppressive Agents. Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology. Springer. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN   978-3-642-65806-8.
  29. ↑ Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients". JAMA. 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010.
  30. ↑ Segaloff A, Horwitt BN, Carabasi RA, Murison PJ, Schlosser JV (1955). "Hormonal therapy in cancer of the breast. VIII. The effect of dihydrotestosterone (androstanolone) on clinical course and hormonal excretion". Cancer. 8 (1): 82–86. doi: 10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R . PMID   13231036.
  31. ↑ Blackburn CM, Childs DS (March 1959). "Use of 2 alpha-methyl androstan-17 beta-ol, 3-one (2-methyl dihydrotestosterone) in the treatment of advanced cancer of the breast". Proceedings of the Staff Meetings of the Mayo Clinic. 34 (5): 113–126. PMID   13658242.
  32. ↑ Goldenberg IS, Hayes MA (1961). "Hormonal therapy of metastatic female breast carcinoma. II. 2alpha-Methyl dihydrotestosterone propionate". Cancer. 14 (4): 705–706. doi: 10.1002/1097-0142(199007/08)14:4<705::AID-CNCR2820140405>3.0.CO;2-I . PMID   13706491. S2CID   20924879.
  33. ↑ Thomas AN, Gordan GS, Lowe R (1962). "Antitumor efficacy of 2alpha-methyl dihydrotestosterone propionate in advanced breast cancer". Cancer. 15: 176–178. doi: 10.1002/1097-0142(196201/02)15:1<176::AID-CNCR2820150124>3.0.CO;2-N . PMID   13920749. S2CID   71255788.
  34. ↑ Sittig M (22 October 2013). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). William Andrew Publishing. pp. 1402–. ISBN   978-0-8155-1856-3.
  35. 1 2 3 4 5 6 7 Brotherton J (1976). Sex Hormone Pharmacology. Academic Press. pp. 19, 43, 336, 355. ISBN   978-0-12-137250-7.
  36. ↑ Krüskemper HL (22 October 2013). Anabolic Steroids. Elsevier. pp. 196–. ISBN   978-1-4832-6504-9.
  37. 1 2 3 4 5 6 7 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 640–. ISBN   978-1-4757-2085-3.
  38. 1 2 3 4 5 6 7 8 9 10 Llewellyn W (2009). Anabolics. Molecular Nutrition Llc. pp. 19, 163. ISBN   978-0967930473.
  39. 1 2 3 4 5 Bagatell C, Bremner WJ (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 149, 325. ISBN   978-1-59259-388-0.
  40. 1 2 3 Jones TH (2009). Advances in the Management of Testosterone Deficiency. Karger Medical and Scientific Publishers. pp. 40–. ISBN   978-3-8055-8622-1.
  41. 1 2 Mozayani A, Raymon L (18 September 2011). Handbook of Drug Interactions: A Clinical and Forensic Guide. Springer Science & Business Media. pp. 656–. ISBN   978-1-61779-222-9.
  42. ↑ Grino PB, Griffin JE, Wilson JD (February 1990). "Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone". Endocrinology. 126 (2): 1165–1172. doi:10.1210/endo-126-2-1165. PMID   2298157.
  43. ↑ Wilderer PA (1 September 2010). "Bioassays for Estrogenic and Androgenic Effects of Water Constituents". Treatise on Water Science, Four-Volume Set. Newnes. pp. 1805–. ISBN   978-0-444-53199-5.
  44. ↑ Malven PV (12 January 1993). Mammalian Neuroendocrinology. CRC Press. pp. 228–. ISBN   978-0-8493-8757-9.
  45. 1 2 Nieschlag E, Behre HM, Nieschlag S (26 July 2012). Testosterone: Action, Deficiency, Substitution. Cambridge University Press. pp. 61–. ISBN   978-1-107-01290-5.
  46. ↑ Diamanti-Kandarakis E (September 1999). "Current aspects of antiandrogen therapy in women". Current Pharmaceutical Design. 5 (9): 707–723. doi:10.2174/1381612805666230111201150. PMID   10495361.
  47. 1 2 3 4 5 Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN   978-3-88763-075-1.
  48. ↑ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 261–. ISBN   978-94-011-4439-1.
  49. ↑ Newsweek. Newsweek. 1953.
  50. ↑ New and Nonofficial Drugs. Lippincott. 1958.
  51. ↑ Lunenfeld B, Oettel M (2009). "Therapeutic potential of testosterone gels". Aging Health. 5 (2): 227–245. doi:10.2217/ahe.09.6. ISSN   1745-509X.
  52. 1 2 List PH, Hörhammer L (12 March 2013). Chemikalien und Drogen: Teil B: R, S. Springer-Verlag. pp. 523–. ISBN   978-3-642-66377-2.
  53. ↑ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 16 November 2016.
  54. ↑ "Drug Product Database - Health Canada". Health Canada. 18 March 2010. Retrieved 13 November 2016.
  55. ↑ Karch S (21 December 2006). Drug Abuse Handbook, Second Edition. CRC Press. pp. 30–. ISBN   978-1-4200-0346-8.
  56. ↑ "The World Anti-Doping Code: The 2020 Prohibited List" (PDF). World Anti-Doping Agency . Retrieved 28 December 2019.
  57. 1 2 "Androgen replacement therapy". AdisInsight. Springer Nature Switzerland AG.
  58. 1 2 "Dihydrotestosterone-transdermal". AdisInsight. Springer Nature Switzerland AG.
  59. ↑ Nelms M, Sucher KP, Lacey K, Roth SL (16 June 2010). Nutrition Therapy and Pathophysiology. Cengage Learning. pp. 766–. ISBN   978-1-133-00809-5.
  60. ↑ Mantovani G (6 October 2007). Cachexia and Wasting: A Modern Approach. Springer Science & Business Media. pp. 673–. ISBN   978-88-470-0552-5.
  61. 1 2 Gruber CJ, Wieser F, Gruber IM, Ferlitsch K, Gruber DM, Huber JC (December 2002). "Current concepts in aesthetic endocrinology". Gynecological Endocrinology. 16 (6): 431–441. doi:10.1080/gye.16.6.431.441. PMID   12626029. S2CID   37424524.
  62. ↑ Sam S (February 2015). "Adiposity and metabolic dysfunction in polycystic ovary syndrome". Hormone Molecular Biology and Clinical Investigation. 21 (2): 107–116. doi:10.1515/hmbci-2015-0008. PMID   25781555. S2CID   23592351.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.